Research Focus

Former Employee. Medicine; Research Stdy Specialist

Recent additions – View all

1. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors

   Meeting Abstract

   Schwartz, G. K.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M.
   Journal of Clinical Oncology (2009)

   Fulltext@MSK | Save
2. Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies

   Meeting Abstract

   Stephenson, J. J.; Lewis, N.; Martin, J. C.; Ho, A.; Li, J.; Wu, K.; Pace, L.; Eder, J. P.; Schwartz, G. K.
   Journal of Clinical Oncology (2008)

   Fulltext@MSK | Save
3. A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

   Meeting Abstract

   Schwartz, G. K.; Yazji, S.; Mendelson, D. S.; Dickson, M. A.; Johnston, S. H.; Wang, E. W.; Shannon, P.; Pace, L.; Gordon, M. S.
   EJC Supplements (2008)

   Fulltext@MSK | Save